Anzeige
Meldung des Tages: Vom Prototyp zum Patent: CiTech sichert sich Schutz im größten Defence-Markt der Welt

Inhibrx Biosciences News

Aktie
WKN:  A40C2U ISIN:  US45720N1037 US-Symbol:  INBX Branche:  Biotechnologie Land:  USA
77,97 $
+0,62 $
+0,80%
66,071 € 26.02.26
Depot/Watchlist
Marktkapitalisierung *
987,31 Mio. €
Streubesitz
7,31%
KGV
-9,60
Index-Zuordnung
-

Inhibrx Biosciences News

16.12.25 - PR Newswire
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program PR Newswire
14.11.25 - PR Newswire
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire
04.11.25 - PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire
23.10.25 - PR Newswire
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and ...
22.10.25 - PR Newswire
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer ...
13.08.25 - PR Newswire
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Reports First Quarter 2025 Financial Results PR Newswire
01.04.25 - PR Newswire
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »